A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

A PHASE 1, OPEN-LABEL, 2-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF [14C]PF-07976016 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07976016 IN HEALTHY MALE PARTICIPANTS USING A [14C]-MICROTRACER APPROACH

The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.

Inclusion Criteria:

• Males, 18 to 65 years of age
• BMI 17.5 to 32 kg/m2 and a total body weight >50 kg (110 lb)
• Willing and able to comply with all study procedures

Exclusion Criteria:

• History of irregular bowel movements or lactose intolerance
• Any medical or psychiatric condition or laboratory abnormality or other condition that may increase the risk of study participation
• Use of any prohibited or concomitant medication(s)
• Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
• Positive urine drug test
• History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
• Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day
• Previous administration of an investigational product within 30 days preceding the first dose of study medicine in this study.